| Literature DB >> 27886819 |
Abstract
There is interindividual variability in the pharmacodynamic response to antiplatelet medications. High on-treatment platelet reactivity, reflecting a failure to achieve adequate platelet inhibition, is associated with a higher risk for thrombotic events. Low on-treatment platelet reactivity, or an enhanced response to antiplatelet medications, has been linked to a higher risk for bleeding. There is evidence for the prognostic value of platelet function testing for risk prediction. This review presents the current evidence regarding platelet function testing in patients undergoing percutaneous cardiac intervention and coronary artery bypass grafting. The possible role of platelet function testing for individualized antiplatelet treatment is highlighted. Copyright ÂEntities:
Keywords: CABG; Guidance of treatment; PCI; Platelet function testing; Platelet reactivity; Risk prediction; Tailored antiplatelet therapy; Transfusion algorithm
Mesh:
Substances:
Year: 2017 PMID: 27886819 DOI: 10.1016/j.iccl.2016.08.011
Source DB: PubMed Journal: Interv Cardiol Clin ISSN: 2211-7458